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AbstrACt
Introduction Preterm birth (PTB) results from 
heterogeneous influences and is a major contributor to 
neonatal mortality and morbidity that continues to have 
adverse effects on infants beyond the neonatal period. This 
protocol describes the procedures to determine molecular 
signatures predictive of PTB through high-frequency 
sampling during pregnancy, at delivery and the postpartum 
period.
Methods and analysis Four hundred first trimester 
pregnant women from either Myanmar or Thailand of 
either Karen or Burman ethnicity, with a viable, singleton 
pregnancy will be enrolled in this non-interventional, 
prospective pregnancy birth cohort study and will be 
followed through to the postpartum period. Fortnightly 
finger prick capillary blood sampling will allow the 
monitoring of genome-wide transcript abundance in 
whole blood. Collection of stool samples and vaginal 
swabs each trimester, at delivery and postpartum will 
allow monitoring of intestinal and vaginal microbial 
composition. In a nested case–control analysis, 
perturbations of transcript abundance in capillary blood 
as well as longitudinal changes of the gut, vaginal and 
oral microbiome will be compared between mothers 
giving birth to preterm and matched cases giving 
birth to term neonates. Placenta tissue of preterm 
and term neonates will be used to determine bacterial 
colonisation as well as for the establishment of coding 
and non-coding RNA profiles. In addition, RNA profiles 
of circulating, non-coding RNA in cord blood serum will 
be compared with those of maternal peripheral blood 
serum at time of delivery.
Ethics and dissemination This research protocol that 
aims to detect perturbations in molecular trajectories 
preceding adverse pregnancy outcomes was approved 
by the ethics committee of the Faculty of Tropical 
Medicine, Mahidol University in Bangkok, Thailand 
(Ethics Reference: TMEC 15–062), the Oxford Tropical 
Research Ethics Committee (Ethics Reference: OxTREC: 
33–15) and the local Tak Province Community Ethics 
Advisory Board. The results of this cooperative project 
will be disseminated in multiple publications staggered 
over time in international peer-reviewed scientific 
journals.
trial registration number NCT02797327; Pre-results.
strengths and limitations of this study
 ► The prospective study design by building a pregnan-
cy–delivery cohort.
 ► The nature of the proposed systems approach, a ho-
listic approach in which investigators do not need 
to choose the parameters that will be measured 
as it will by default simply be ‘everything’, and it is 
in that sense that these approaches are inherently 
unbiased, is a strength on one hand but has its lim-
itations on the other hand (eg, gene panel selection 
bias or technical bias such as sequencing bias in 
library construction or amplification bias).
 ► High-frequency sampling throughout the entire 
pregnancy, facilitated by enrolment in the first tri-
mester, which is ensured by precise estimation of 
gestational age via early ultrasound scan for all par-
ticipants, enables to evaluate transcript abundance 
in the peripheral whole blood that contains granu-
locytes and mononuclear cells in a genome-wide 
scale.
 ► The fact that women with presumably complicated 
pregnancies or women who potentially require a 
caesarean section (eg, history of caesarean section) 
are excluded from the study since advanced medical 
services due to the rural setting and access to clin-
ic-based but only limited access to hospital-based 
facilities might introduce a selection or exclusion 
bias.
 ► Bias due to missing data and protocol deviations: 
resulting from the high-frequency sampling, it is ex-
pected that some women will not be able to provide 
all per-protocol samples.
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IntroduCtIon 
Preterm birth (PTB), defined as delivery before 37 weeks 
of gestation, is a major cause of neonatal mortality and 
morbidity.1 2 In 2010, the estimated number of neonates 
born before 37 weeks of gestation was 14.9 million world-
wide, which translates into an incidence of 11.1% of all 
live births, with higher rates in developing countries.3 
PTB is the most important cause of neonatal death world-
wide and accounts for a large proportion of under-5 
infant mortality.4 5 In addition to neonatal mortality, the 
proportion of preterm infants with long-term physical and 
mental impairments is higher when compared with term 
neonates.6 Not surprisingly, survival of preterm neonates 
is associated with the gestational age at delivery and the 
socioeconomic setting at birth as there is a huge gap 
when comparing survival in low-income and middle-in-
come countries (LMICs) to high-income countries.3 7 
The mortality risk of preterm infants compared with term 
infants in the proposed study population is significantly 
higher for early premature infants defined as delivery 
at ≥28–<34 weeks of gestation (OR 9.5, 95% CI 5.4 to 
16.5, p<0.001), while the mortality risk for late premature 
infants defined as delivery at 34 to <37 weeks of gesta-
tion (OR 1.4, 95% CI 0.8 to 2.6, p=0. 3) is not significantly 
different.8 
The aetiology of PTB is variable. Approximately 
one-third of PTBs are iatrogenic, often a result of adverse 
events (AEs) such as pre-eclampsia, eclampsia or intra-
uterine growth restriction.9 Spontaneous PTB accounts 
for the other two-thirds of PTB; however, in the majority 
of the cases, the causative reasons remain elusive.10 A 
number of proxies for spontaneous PTB have been iden-
tified, such as genital tract infections, inherited predispo-
sition, uterine ischemia and over distension, decline in 
progesterone action, disruption of maternal-fetal toler-
ance, cervical dysfunction/weakness or endocrine disor-
ders, such as gestational diabetes mellitus (GDM), and 
changes in the placental microbial composition, which 
can lead to the production of proinflammatory cytokines 
and subsequent inflammation.11–15 Tropical communi-
cable diseases (eg, malaria and tuberculosis) are more 
prevalent in LMICs and have been identified as a contrib-
utor to the burden of PTB in these settings.16–18
It is generally accepted that PTB results from hetero-
geneous influences that can lead to preterm labour or 
premature rupture of fetal membranes with subsequent 
uterine contractions. The current understanding of 
preterm labour is that due to a shift in signalling path-
ways, the chain of events causing the myometrium to 
switch from a quiescent to a contractile state is triggered 
too early. Priming leucocytes in peripheral blood and 
leucocyte accumulation in uterine tissue seem to play a 
key role in the activation of this pathway.19–21 While in 
term deliveries this process is activated physiologically, 
in preterm labour external, environmental and internal 
influences can lead to alterations in the composition of 
immunomodulating agents and activate a pathway, which 
Romero et al22 referred to as ‘common pathway’, ulti-
mately leading to preterm labour.
In the event of microbial-induced preterm labour, 
bacteria can gain access to the amniotic cavity either via 
an ascending route (eg, from the lower genital tract) or a 
haematogenous route (eg, microbes from the oral cavity); 
an abnormal vaginal microbiota or vaginal dysbiosis is 
known to be associated with PTB.13 23 Bacterial vaginosis 
is a known risk factor for PTB and other adverse preg-
nancy outcomes.24 25 The vaginal microbial composition 
changes over the course of pregnancy but whether the 
vaginal microbiome is altered when comparing micro-
bial composition between pregnant women delivering 
at term versus preterm is not clear.26–28 Similar to vaginal 
microbial composition, the composition of the intestinal 
microbiome undergoes changes during pregnancy.29 30 
Whether there are implications of intestinal dysbiosis on 
pregnancy outcome is not yet known.
A successful pregnancy relies on complex molecular 
and biochemical processes that are essential for the differ-
entiation, development and preservation of placental 
tissue as well as fetal development and maturation.31 32 
To ensure adequate functions of the placenta, genes are 
upregulated and downregulated adaptively depending on 
progress of the pregnancy and the exposure to environ-
mental stressors.32 In analogy to gene regulation, levels of 
placental DNA methylation and post-translational modi-
fication of histones, an epigenetic process that does not 
involve modification of the DNA sequence, are signifi-
cantly altered in suboptimal maternal conditions, such 
as GDM, pre-eclampsia and obesity.33–35 Technological 
breakthroughs in the field of high throughput molec-
ular profiling technologies enable assessment of these 
biochemical processes by simultaneous measurement 
of abundance or activity of all elements constitutive of a 
given system (genome, transcriptome, proteome, micro-
biome and so on).
Molecular signatures are sets of genes, proteins, genetic 
variants or other variables that can be derived from 
systems-scale profiling and used as markers for a partic-
ular phenotype.36 These so-called systems approaches 
have revolutionised biomedical research by enabling 
the phenotyping of individuals and their environment 
at unprecedented depth and play a pivotal role in estab-
lishing personalised medicine.37
Approaching the dilemma of PTB with a structured 
systems approach that builds on monitoring perturba-
tions in blood transcriptome and human microbiome 
profiles during pregnancy might enable observations of 
significant changes in molecular signatures peripartum 
and has the potential to gear researchers and clinicians 
towards a predictive tool for risk assessment of PTB in the 
early stages of pregnancy.38 39 To accomplish this, we aim to 
obtain holistic multiomics data on preterm delivery by inte-
grating transcript abundance (the expressed fraction of 
genes of a genome) and microbial composition of the gut 
and vaginal microbiome with multilevel data of placental 
tissue and cord blood. Notably, the introduction of an 
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additional dimension with high frequency sampling and 
profiling is meant to enable the identification of molec-
ular changes underlying pathogenic processes prior to 
onset of symptoms. This so-called molecular interception 
approach is meant to provide novel avenues for the devel-
opment of preventive strategies aiming to interrupt such 
processes and avert the adverse clinical outcomes.
MEthods And AnAlysIs
study design
This trial is designed as non-interventional prospective 
cohort study in pregnant women without severe medical 
or obstetric complications to assess potential differences 
in whole blood transcript abundance and changes in gut, 
vaginal and oral microbial composition from the first 
trimester until 12 weeks postpartum associated with PTB. 
In addition, bacterial composition as well as RNA profiles 
from placenta and cord blood serum will be studied.
setting
This trial is carried out as cooperation between Shoklo 
Malaria Research Unit (hereafter referred to as SMRU), 
Mae Sot, Thailand, and Sidra Medicine (hereafter 
referred to as Sidra), Doha, Qatar. SMRU is a field station 
of the Faculty of Tropical Medicine, Mahidol University, 
Bangkok, Thailand, and is part of the Mahidol-Oxford 
Research Unit. For more than three decades, SMRU 
has contributed to and combined health services and 
research in rural and disadvantaged migrant and refugee 
populations living on the Thai–Myanmar border. SMRU 
recruits study participants alongside the Thailand–
Myanmar border and collects clinical data and study 
related samples. Sidra is part of Qatar Foundation for 
Education, Science and Community Development. The 
Research branch of Sidra serves as a hub for biomedical 
research in Qatar and aims to understand mechanisms 
of disease aiming to develop modern tools to diagnose 
disease and improve health outcomes of women and chil-
dren. Sidra analyses samples as described in the methods 
section below.
Participants and recruitment
In total, 400 study participants will be recruited at SMRU 
antenatal care (ANC) clinics on the Thailand–Myanmar 
border. All eligible pregnant women will be approached 
and informed about the background of the study in their 
preferred language by a trained counsellor. Gestational 
age will be estimated by early ultrasound scan by locally 
trained technicians40; subjects with an estimated gesta-
tional age from 8+0 to less than 14+0 (weeks+days) weeks 
will be included. Inclusion and exclusion criteria are 
summarised below.
Inclusion criteria
 ► Pregnant woman willing and able to give informed 
consent.
 ► Karen or Burman ethnicity.
 ► Age 18-49 years.
 ► Healthy, with viable singleton first trimester (8+0 to 
<14+0 weeks) pregnancy.
 ► Planning to deliver at SMRU clinic.
 ► Able (in the Investigators opinion) and willing to 
comply with study requirements.
Exclusion criteria
 ► Emergency obstetric care required.
 ► Pregnant woman with medical or obstetrics complica-
tions that would make it difficult to comply with study 
requirements (in the investigator’s opinion).
sample size
Since the number of samples necessary for the identification 
of a robust signature is variable, sample size requirements 
will depend on the amplitude of the difference between 
and the variability within study groups. Best practices in the 
microarray field dictate utilisation of at least two indepen-
dent sets of samples for the purpose of validating candidate 
signatures (or profiles).41 However, in the absence of prior 
high-resolution temporal profiling data in this setting, a 
pragmatic approach was chosen to determine the samples 
size: recruitment of a number of cases and controls from 
which a candidate biomarker signature with potential clin-
ical relevance can reasonably be expected to be found. The 
number of cases was set to 30, which means that we consider 
it unlikely that a signature would be sufficiently robust to be 
of clinical relevance if it required a higher number of cases 
and controls to reach significance. This number is selected 
empirically, but our experience conducting blood transcrip-
tomic studies across a wide range of study settings indicates 
that it would likely be sufficient to identify candidate signa-
tures and assess phenotypic heterogeneity at the molecular 
level.42
With a target number of cases being set (in our case to 
30), the estimation of the cohort size (n=400) is then simply 
based on documented PTB rates for the study population, 
which is approximately 8%. The rate of PTB in this popula-
tion is on the lower end of the spectrum, and we also consid-
ered the risk that, as is the tradition, some women deliver at 
home whereas the study needs to capture unit births.
study and sampling procedures
Table 1 as well as figures 1 and 2 provide an overview of the 
study conduct and timing regarding patient related data, 
assessment and samples; details on routine ANC procedures 
are provided in the online supplementary file.
Below is a brief narrative of samples taken to achieve 
study objectives.
1. To obtain RNA for gene expression data, small whole 
blood samples (50 µL) are collected via finger prick 
sampling into a capillary straw and mixed with a RNA 
stabilising solution.43 44 Total RNA is extracted, and the 
transcriptome signatures of mothers with term and 
preterm infants are compared.45
2. To assess the vaginal microbiome, vaginal swabs are 
collected from the posterior fornix. Four vaginal swabs 
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are taken each time: (1) to extract genomic bacterial 
DNA, (2) to prepare a Gram stain smear to assess the 
Nugent score,46 (3) for metatranscriptomic analysis 
and (4) for analysis of vaginal cytokines.
3. Fresh stool samples are taken and transferred into a 
DNA stabilising solution for analysis of microbial com-
position. A 24-hour food recall is asked each time a 
stool sample is provided to correlate dietary intake 
with intestinal microbial composition.
4. To evaluate the microbial composition of the oral cavi-
ty, saliva samples are taken twice.
5. To assess potential microbial colonisation in the fe-
toplacental compartment, placental tissue as well as 
cord blood and maternal blood samples are harvest-
ed at delivery. RNA profiles (mRNA, long non-coding 
and short non-coding) will be established from the 
placenta tissue. Serum from cord blood and mater-
nal blood at delivery will be used to isolate circulating 
RNA (long non-coding and short non-coding) as well 
as to determine the concentration of hormones such 
as adrenocorticotropic hormone (ACTH), cortisol and 
cytokines.
6. In the event of a febrile episode, a set of capillary blood, 
stool and vaginal swab samples is repeated. Moreover, 
a standard fever screening battery (available in the on-
line supplementary file) is triggered, and clinical and 
treatment information (eg, antibiotic use) will be cap-
tured. Whether high frequency sampling is accepted 
will be assessed by a survey conducted on enrolment 
and after delivery.
After the postpartum period, the researchers will follow 
the mothers and infants for a total period of 2 years to 
build a mother–infant cohort. Rationale for following the 
progeny and exact procedures will be shared in a separate 
publication of the respective research protocol.
Primary outcome measures
The primary outcome is the characterisation of the 
molecular signature of women with a preterm delivery. In 
a nested case–control analysis of the study cohort, these 
cases are then compared with a control group of women 
with a term delivery and an uneventful pregnancy, 
matched by parity, maternal age, ethnicity, first trimester 
body mass index and smoking status.
Table 1 Study timeline and conduct
Screening Baseline Follow-up
Unwell 
episode Birth Post-partum
Viable singletons pregnancy X
Obstetric ultrasound* X X X
Eligibility assessment X
Informed consent X
Demographics X
Medical and obstetric history X
Concomitant medications X X X X X
Physical examination X X X X X
Universal pregnancy screening,
for example, malaria smear, 
CBC and OGTT†
X (X)†
Sample maternal 100 µL 
capillary blood
X X ‡ X§ X¶ X**
Sample vaginal swab, stool 
specimen and 24-hour food 
recall
X†† X†† X X X‡‡
Acceptability survey X X
Sample saliva X§§ X
Sample placenta, cord 
blood and maternal venous 
blood
X
*Fetal growth scans will be scheduled on a 6-weekly basis.
†OGTT at 24–26 weeks of gestation; repeated at 12 weeks postpartum if positive during pregnancy.
‡2-weekly; if the woman attends all expected 15 visits total blood is 1.5 mL.
§If the woman attends for an unwell visit (estimated 5%–10% of women) additional 100 µL.
¶If delivery at SMRU clinic, then additional 100 µL.
**At 1, 2 and 3 months postpartum, including maternal haematocrit.
††In each trimester of pregnancy: 8–14, 20–22 and 34–35 weeks.
‡‡Vaginal swab samples at 4–6 weeks and at 3 months.
§§At 24–26 weeks of gestation.
CBC, complete blood count; OGTT, oral glucose tolerance test.
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secondary outcome measures
 ► Identified biomarker signatures predictive of poor 
fetal growth.
 ► Describe the variation in molecular signatures during 
pregnancy and postpartum in:
i. Individual women (intrapregnancy).
ii. Between women (interpregnancy).
 ► Determine the acceptability of frequent sampling in 
the study population.
 ► Preliminary data on the potential of a system approach 
in detecting infectious events before the onset of clin-
ical symptoms or in the absence of clinical symptoms.
Methodologies of sample and data processing
Blood transcriptional profiling
Blood transcript abundance will be measured via RNA 
sequencing and a high-throughput quantitative PCR plat-
form and assayed through ‘transcriptome fingerprinting’.
Figure 1 Timeline of study procedures. OGTT, oral g lucose tolerance test 
Figure 2 Study-specific procedures. SMRU, Shoklo Malaria Research Unit. 
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RNAseq
This will be carried out by the Sidra genomics facility. 
Libraries will be constructed from globin-reduced RNA 
using the Illumina TruSeq RNA Sample Preparation kit 
according to manufacturer’s instructions. Libraries will 
then be clustered on a flow-cell using the TruSeq Single 
Read Cluster Kit followed by paired-end sequencing of 
150 nucleotide fragments on a HiSeq2500 sequencer 
(Illumina) with targeted read depth of 20 M reads/
sample. RNAseq alignment and quality control will be 
carried out by the Sidra bioinformatics core.
Transcriptome fingerprinting assay
A manuscript describing this assay is in preparation. 
Briefly, a collection of 985 blood transcriptome profiles 
spanning 16 different diseases (autoimmune, infectious, 
cancer and genetic) or physiological states (pregnancy) 
will be used as a basis for the identification of 382 gene 
sets (modules) capturing a wide repertoire of transcrip-
tional signatures. The gene sets will be further grouped 
in 38 classes, from which 66 representative modules will 
be selected. Four representative genes/module will be 
subsequently selected, resulting in a set of 264 target and 
8 housekeeping transcripts used as a basis for targeted 
assay development. In this study, abundance of these 272 
transcripts will be measured on a Fluidigm biomark high 
throughput PCR instrument. Cycle threshold (Ct) values 
will be generated and converted to fold changes (FCs) to 
reference samples. First, delta Ct values will be calculated 
by subtracting the geometric mean of the housekeeping 
genes to control for different starting amounts, then 
delta-delta Ct values will be calculated by subtracting the 
geometric mean of the reference sample to control for 
potential plate batch effects, and finally FC values will be 
calculated by taking 2 to the power of the negative delta-
delta Ct.47 48 Module FC values will be calculated as the 
geometric mean of the FC values of the four genes in the 
module.
Microbial nucleic acid isolation and 16S rRNA gene sequencing (all 
samples intended for microbiome analysis)
Microbial genomic DNA will be extracted from the stool 
samples and vaginal swabs using MoBio Power Fecal isola-
tion Kit and the MoBio Power Soil isolation Kit (MoBio 
Laboratories, Carlsbad, California, USA) respectively, 
from saliva samples using automated extraction with 
QIAsymphony DSP DNA kit on QIAsymphony (Qiagen, 
Germany) according to the manufacturer’s instruction. 
Samples will be stored at −20°C until sequencing. The 
quantity of purified DNA will be measured at 260/280 
absorbance using a NANODROP spectrophotom-
eter (Thermo Scientific), and the quality will be evalu-
ated by electrophoretic fractionation in 0.5× TBE gel 
at 0.5% agarose (w/v), stained with Midori Green and 
will be recorded using a Bio-Rad Molecular Imager Gel 
DOC XR+ Imaging System.
The V1–V3 regions of the 16S rRNA will be amplified 
from microbial genomic DNA using the different forward 
primer: 27F with 12 base pairs (bp) golay barcodes and 
Illumina 5′ adapter for each sample and common reverse 
primer 534 R.49 In brief, PCR will be performed in trip-
licate in a 50 µL reaction mixture containing 10 ng of 
template DNA and 2× KAPA HiFi HotStart Ready Mix. 
The following thermal cycling conditions will be used: 
5 min of initial denaturation at 94°C; 30 cycles of dena-
turation at 94°C for 30 s, annealing at 62°C for 30 s and 
elongation at 72°C for 30 s; and a last step at 72°C for 
10 min. The amplified PCR products of approximately 
625 bp in size from each sample will be pooled in equi-
molar concentration. This pooled PCR product will be 
purified through E-Gel SizeSelect Agarose Gels Starter 
Kit, 2% (Thermo Fisher Scientific). High-throughput 
sequencing will be performed on an Illumina MiSeq 
2×300 platform (Illumina, San Diego, California, USA) 
at Sidra in accordance with manufacturer’s instructions. 
Image analysis and base calling will be carried out directly 
on the MiSeq.
Demultiplexed sequencing data will be analysed using 
QIIME software V.1.9.0 pipeline.50 FASTQ files will be 
converted into FASTA files, and all demultiplexed files 
will be concatenated into a single file. Further analysis will 
be performed as previously reported.51 52 Sequence align-
ments will be done against the Greengenes core set.53
Alpha diversity will be measured by R software, using 
the phyloseq package (1,2).54 Beta diversity will be repre-
sented using weighted UniFrac distance measure, and 
contributions to the differences in the beta diversity will 
be presented as principle coordinate analysis as proposed 
in QIIME.55
Placenta and blood serum transcriptional profiling
Total RNA and long non-coding RNA will be isolated 
from 30 mg of frozen placenta tissue using the RNeasy kit 
(Qiagen) or from 100 µL serum using the RNeasy Serum/
Plasma kit (Qiagen) while short non-coding RNA will be 
isolated from 30 mg of frozen placenta tissue using the 
miRNeasy kit (Qiagen) or from 100 µL serum using the 
miRNeasy Serum/Plasma kit (Qiagen). Libraries will be 
prepared using TruSeq RNA Library Prep kit (Illumina) 
according to the manufacturer’s instructions and RNAseq 
using the Illumina HiSeq 4000 platform. Paired-end reads 
(300 cycles) will be performed. Sequence data quality will 
be examined using the FastQC tool, followed by the reads 
mapped to the human reference genome (hg 19).
Detection and quantification of bioactive molecules
Serum (originating from cord blood or maternal blood 
at birth) levels of ACTH, cortisol and cytokines will be 
tested using commercially available ELISA kits (R&D) 
according to the manufacturer’s instructions.
statistical analysis
Descriptive data
Appropriate statistical tests will be applied to analyse and 
present descriptive data.
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RNASeq data
The data in *.fastq files will be assessed to investigate the 
read quality and experimental artefacts including sample 
contamination, PCR and sequencing errors and so on. 
Sequence alignment will then be performed, reads will 
be mapped to the human reference genome (hg19) and 
quality will be reassessed. Postalignment, reads will be 
deduplicated, quantified to identify expression level of 
genes/transcripts and normalised according to a suitable 
method. Genes will be filtered based on their normalised 
signal intensity values with a specified cut-off.
The statistical environment R will be used to perform 
statistical analysis along with the PartekR FlowR. Appro-
priate statistical test will be employed to identify genes 
showing statistically significant differences with p value 
cut-off ≤0.05 and multiple testing correction (FWER/
FDR) method to control false positives and false nega-
tives. The FC in gene expression will also be measured. 
The set of differentially expressed genes identified by 
measuring FC difference and/or using p<0.05 cut-off will 
be retained and used further for the downstream anal-
ysis including Gene Ontology (GO), Gene Enrichment 
and Pathway Analysis. Hierarchical clustering will be 
performed to investigate the expression profiles in the 
datasets. Transcriptional modular analysis will also be 
performed as described previously.56 For the longitudinal 
pregnancy data, mixed effects models will be run using 
the lme4 package in R to compare modular trajectories 
of uncomplicated pregnancies and preterm.57
Microbiome analysis
Alpha diversity measures such as Observed, Chao1, 
Shannon and Simpson indices will be analysed using 
minitab17 (Minitab statistical software). Kruskal-Wallis 
tests will be used to compare the statistical difference 
among diversities between the categories. P values lower 
than 0.05 will be considered statistically significant. A 
multivariate analysis between the relative abundance 
of microbiota and clinical metadata will be done using 
MaAsLin.58
Multiomics analysis
Exploratory and unsupervised data analyses of single 
omics datasets will be performed along with principal 
component analysis to capture trends/variations in 
the datasets. Then, the different omics datasets will be 
integrated and compared with understand some of the 
complex steps and processes using correlation anal-
ysis, regression analysis, meta-data analysis and pathway 
analysis. Correlation analysis will be used to measure 
the strength and directionality of pairwise relationships 
between different datasets. Metadata analysis will be 
used to visually depict sample attributes such as pheno-
type, molecular subtypes, clinical parameters and time 
points. Venn diagrams will be used to display the overlap 
between different omics datasets. An integrated pathway 
analysis will also be performed with statistically significant 
variables identified from single omics datasets. Based on 
the significant variables, a prediction model will be built 
for monitoring of pregnancy complications.
Patient and public involvement
Historical data from monitoring pregnant women in this 
area show that PTB is problematic due to the difficulty 
in accessing high-level neonatal care and due to the asso-
ciation with neonatal death. Study participants were not 
directly involved in the study design, the elaboration of 
research questions and outcome measures or the recruit-
ment and conduct of the study. However, the protocol was 
reviewed and approved by the local Tak Province Commu-
nity Ethics Advisory Board (T-CAB). T-CAB members are 
representatives of the local community who act as a bridge 
between researchers and the local population.59 Their 
role was to advise on ethical and operational aspects of 
the study (eg, appropriate informed consent procedures, 
compensation and confidentiality), and they will provide 
a mechanism to inform the community of the results of 
this study. Additionally, the researchers will involve study 
participants to assess whether the study procedures and 
frequency of sampling is accepted by conducting accept-
ability surveys at study enrolment and study completion.
Study results that can positively change clinical prac-
tice will be disseminated through the local annual health 
meeting and, if relevant, by health education at the ante-
natal clinics. Individual data will not be reported back to 
participants.
EthICAl ConsIdErAtIons
The population served by SMRU clinics is predomi-
nantly migrant workers from Myanmar living alongside 
the Thailand–Myanmar border. SMRU has been working 
with the border communities for over three decades, a 
long experience of working with vulnerable populations. 
SMRU medics, nurses, midwives and health workers are 
recruited from the same areas as the patient population 
and are sensitive to their needs. All communication is 
conducted in the preferred language of the patient.60 
Trained counsellors will provide informed consent once 
a pregnant woman has a confirmed viable singleton preg-
nancy and after routine enrolment procedures for ANC 
are completed. The participant must personally sign 
and date the latest approved version of the informed 
consent form (ICF) before any study-specific procedures 
are performed. The participant information sheet and 
ICF detail no less than the exact nature of the study and 
the implications and constraints of the protocol and the 
known side effects and any risks involved in taking part. 
It will be clearly stated that the participant is free to with-
draw herself from the study at any time for any reason 
without prejudice to future care and with no obligation 
to give the reason for withdrawal.
Written informed consent will then be obtained by 
means of participant dated signature and dated signature 
of the person who presented and obtained the informed 
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consent (or thumbprint in the case of non-literate 
participants).
Confidentiality and access to data
Confidentiality and access to data are according to Stan-
dard Protocol Items: Recommendations for Interven-
tional Trials.61 All study-related information is stored 
securely at the study site. Participant information is stored 
in locked file cabinets in areas with limited access. To 
maintain participants’ confidentiality, all laboratory speci-
mens, reports, collected data and administrative forms are 
identified by a coded ID number only. The participants 
are assigned a unique study ID, led by the study acronym 
MSP (eg, the first participant will be coded as MSP-001). 
All records that contain names or other personal identi-
fiers, such as locator forms and ICFs, are stored separately 
from study records identified by code number. All study 
data are entered into an online MACRO database for later 
analysis. The database is secured with password-protected 
access systems. Forms, lists, logbooks, appointment books 
and any other listings that link participant ID numbers 
to other identifying information are stored in a separate, 
locked file in an area with limited access.
Only SMRU staff with explicit permission has access to 
the patient-related data. The data will be made available 
to colleagues and peer reviewers on request. Variables 
containing sensitive information may be removed before 
sharing datasets.
Once the study is completed, anonymous data will be 
kept at SMRU and securely stored for 10 years.
data monitoring
The principal investigator designated an independent 
monitor to perform a review of ongoing study progress 
and safety. A data monitoring committee is not required 
for an observational study design.
Spontaneously reported AEs are recorded, and severe 
adverse events are reported to the local ethical committee. 
No interim analysis will be carried out and no audit is 
expected during the conduct of the trial.
dIssEMInAtIon
The results of this study will be published in international 
peer-reviewed scientific journals. This project is coopera-
tive, in that each participating principal investigator will 
take the lead in publishing results relating to his or her 
respective clinical or ‘omics’ component. It is also collab-
orative in that integrative analyses across these compo-
nents will be subsequently carried out collectively and 
published. Hence, the researchers anticipate multiple 
publications staggered over time.
data sharing
Due to ethical and security considerations, the data that 
support the findings in this study will be accessible only 
through the Data Access Committee at Mahidol Oxford 
Tropical Medicine Research Unit. The data sharing 
policy can be found here: http://www. tropmedres. ac/ 
data- sharing. The application form can be found in 
the online supplementary file. Transcript profiling data 
will be shared on the NCBI Gene Expression Omnibus 
(GEO). The 16S rRNA sequencing data generated from 
the various microbiome analyses will be stored as a 
bioproject with a unique ID in NCBI for public resource 
as Sequence Read archives. (https://www. ncbi. nlm. nih. 
gov/ bioproject/).
dIsCussIon
The aim of this study is to identify potential predictive 
‘molecular signatures’ associated with PTB as well as 
maternal and neonatal morbidity and mortality in a 
resource-limited setting where infectious diseases such as 
malaria and tuberculosis are more prevalent. Adverse preg-
nancy outcomes like prematurity are important pheno-
types that significantly influence neonatal morbidity and 
mortality, while also impacting life beyond the neonatal 
period.4 5 Emergence of PTB is poorly understood, and 
the causative factors often remain elusive. Among iden-
tified risk factors are genital tract infections, inherited 
predisposition, uterine ischaemia and over distension, 
decline in progesterone action, disruption of maternal 
fetal tolerance, cervical disease or endocrine disorders 
and changes in the placental microbial composition and 
subsequent inflammation.11 12 14 15 GDM, which is also 
associated with iatrogenic PTB, is an emerging concern in 
the study population as well as worldwide and is therefore 
a considerable factor.62–64
To address these various components, we attempt to 
characterise the phenotype ‘preterm’ by integrating 
multilevel omics profiles commencing in early pregnancy 
through to delivery. High throughput technologies can 
capture a wide array of genomic and environmental 
parameters of individuals and play a pivotal role in estab-
lishing a personalised medicine approach.37
Rapid technical advances improved the quality and 
quantity of high-resolution molecular profiling and enable 
to capture of the diversity of a person across a wide array 
of parameters and, not least, improving cost-effectiveness 
of sample analysis.65 Heng et al showed that measurement 
of whole blood gene expression at two time points during 
pregnancy has the potential to predict spontaneous PTB 
when combined with clinical data.39 However, the current 
study is uniquely geared to investigate potential clinical 
utility of ‘molecular interception’ approaches due to the 
increased sampling frequency. Genome-wide transcript 
signatures at an increased sampling frequency will be 
employed to evaluate whether changes in blood tran-
script abundance trajectories precede preterm deliveries 
and can be reproduced in different populations.
Due to the complexity of PTB, perturbations of gut and 
vaginal microbiome will be incorporated in the analysis, 
both of which are influenced by pregnancy. The vaginal 
microbiome is altered when comparing pregnant and 
non-pregnant women.66 67 Moreover, dysbiosis in the 
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vaginal microbiome could be associated with adverse 
pregnancy outcomes and potentially enable the identifi-
cation of pregnant women at risk for PTB at an early stage 
in pregnancy.25–27 Analysis of the vaginal microbiome is 
included in this study to characterise the vaginal bacterial 
composition prepartum, intrapartum and postpartum in 
a study population which, to our knowledge, has not been 
done before and to analyse whether perturbations in this 
microbial niche are associated with preterm delivery. 
Corresponding to vaginal microbiome, the intestinal 
microbial composition also undergoes changes during 
pregnancy.29 68 While data on the association between 
PTB and changes in the intestinal microbiome are 
scant, there is some evidence that the gut microbiome is 
different in mothers with preterm infants.69 Assessment of 
gut and vaginal microbiome in the 3-month postpartum 
period will inform about adaption of bacterial composi-
tion following childbirth. Since there is a link between 
PTB and periodontal disease, association of the oral 
and placental microbial flora will round up this holistic 
approach aimed at unravelling the dilemma of PTB.23
We anticipate that this project that will tag onto routine 
ANC visits, will be feasible and acceptable and can demon-
strate the potential for the use of a ‘systems approach’ in 
the prediction of adverse outcomes and complications 
in pregnancy and early infancy in rural tropical settings. 
The ultimate goal is to identify predictors of PTB that can 
guide the most effective targeted intervention strategies 
for women at risk for PTB in the future. This project is 
even more relevant to the resource poor population that 
SMRU is working with because the burden of mortality 
and morbidity from PTB is significant when only limited 
neonatal care can be provided.
Since only a fraction of the pregnant women in this 
cohort are necessary to achieve the case–control compar-
ison of molecular signatures in term and preterm preg-
nancies, data will be captured from other phenotypes 
(eg, birth weight, small for gestational age or subclinical 
malaria infection). Depending on the quantity and quality 
of the captured data, valid results from any subgroup 
analysis will be made available for the scientific commu-
nity and published in peer-reviewed journals.
The following attributes reflect the strength of this 
protocol:
 ► The prospective study design by building a preg-
nancy–delivery cohort.
 ► The nature of the proposed systems approach, a 
holistic approach in which investigators do not need 
to choose the parameters that will be measured as it 
will by default simply be ‘everything’, and it is in that 
sense that these approaches are inherently unbiased.65
 ► High-frequency sampling throughout the entire preg-
nancy, facilitated by enrolment in the first trimester, 
which is ensured by precise estimation of gestational 
age via early ultrasound scan for all participants, 
enables to evaluate transcript abundance in the 
peripheral whole blood that contains granulocytes 
and mononuclear cells in a genome-wide scale.65
 ► Concerted assessment of the interdependence 
between the elements of blood transcriptome and 
the microbiome component will enable drawing 
inferences on how they mutually influence each 
other and what the consequences for pregnancy 
outcomes are.
 ► Expected favourable acceptability of high-frequency 
small volume finger prick capillary blood sampling 
due to decades of regular malaria (1 to 2 weekly) 
screening at ANC clinics at SMRU as the only 
means of effective control in pregnancy.70 Whether 
high-frequency sampling with the limitation of lack 
of personal benefit is also accepted will be assessed 
by acceptability surveys at study enrolment and study 
completion.
 ► Potential recommendations on sampling time points 
and frequency for further studies depending on 
output of this protocol.
Potential limitations of the study protocol:
 ► Selection and exclusion bias: women with presum-
ably complicated pregnancies or women who will 
potentially require a caesarean section (eg, history of 
caesarean section) are excluded from the study since 
SMRU cannot provide advanced medical services due 
to the rural setting and access to clinic-based but only 
limited access to hospital-based facilities. Dependent 
on the medical and obstetric history, case-by-case 
decision by the attending obstetric doctor and/or 
research physician whether a potential participant 
can be enrolled.
 ► Protocol deviations due to the high-frequency 
sampling: it is expected that some women will not be 
able to provide all per-protocol samples.
 ► Vaginal swabs at delivery will be dependent on the 
timing when the pregnant woman arrives at the clinic. 
Late presentations and/or precipitate deliveries 
might lead to loss of delivery swab samples.
 ► Loss of participants: despite the long history of work 
with the local population of more than 30 years and 
since the majority of SMRU staff originate from the 
local population, both of which are likely to enhance 
the operational feasibility of this ambitious project, 
loss of participants is also expected since the study is 
conducted in a mobile migrant population. For this 
reason, women who are lost before birth outcome will 
be replaced by recruitment of a new participant in 
line with the sample size calculation.
 ► Epidemiological and technical biases that are associ-
ated with gene expression profiling (eg, gene panel 
selection bias or technical bias such as sequencing 
bias in library construction or amplification bias).
In conclusion, should this study deliver significant 
results that are reproducible in other study populations, 
molecular signatures based on a cross-omics approach 
could be a potential tool to predict preterm deliveries in 
the future and allow early/programmed interventions to 
alleviate morbidity and mortality from these deliveries. 
Moreover, we might gain more insight in the origin of 
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preterm deliveries that cannot be diagnosed at this time 
point.
Author affiliations
1Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, 
Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand
2Department of Medicine, Swiss Tropical and Public Health Institute, Basel, 
Switzerland
3Faculty of Medicine, University of Basel, Basel, Switzerland
4Sidra Medicine, Doha, Qatar
5Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
6Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
University of Oxford, Old Road Campus, Oxford, United Kingdom
Acknowledgements The Shoklo Malaria Research Unit is part of the Wellcome 
Trust Mahidol University Oxford Tropical Medicine Research Programme supported 
by the Wellcome Trust of Great Britain (Major Overseas Programme – Thailand Unit 
Core Grant: WT-106698). Sidra Medicine is a member of the Qatar Foundation for 
Education, Science and Community Development.
Contributors DC, RM and FN conceived the overall idea of the project with 
contributions on the details from SAK, AT, AKM and BSAK. TB, RM, DC, AT, SAK, TK, 
MT and DHP wrote the manuscript. TB and SS will collect the data. TB, DC, BSAK, 
SAK, AT and AKM will analyse the samples. TB, DC, BSAK, MT, SAK, AT, AKM, AA, 
JCK, SL, SP, RM, JU, DHP and FN will interpret the data, write the manuscripts and 
disseminate results. All authors read and agreed to the final version of the protocol 
and the publication of the protocol.
Funding Sidra Medicine is the funder of this trial.
Competing interests None declared.
Patient consent Not required.
Ethics approval This research project was approved by the ethics committee 
of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (Ethics 
Reference: TMEC 15–062), the University of Oxford Central University Research 
Ethics Committee (Ethics Reference: OxTREC: 33–15) and the local Tak Province 
Community Ethics Advisory Board. 
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. World Health Organisation. Preterm birth (Fact sheet No. 363). 2016. 
Retrieved from http://www. who. int/ mediacentre/ factsheets/ fs363/ en/
 2. WHO: recommended definitions, terminology and format for 
statistical tables related to the perinatal period and use of a new 
certificate for cause of perinatal deaths. Modifications recommended 
by FIGO as amended. Acta obstetricia et gynecologica Scandinavica 
1976;1977:247–53.
 3. Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, 
and worldwide estimates of preterm birth rates in the year 2010 with 
time trends since 1990 for selected countries: a systematic analysis 
and implications. Lancet 2012;379:2162–72.
 4. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? 
Where? Why? Lancet 2005;365:891–900.
 5. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national 
causes of child mortality: an updated systematic analysis for 2010 
with time trends since 2000. Lancet 2012;379:2151–61.
 6. Mwaniki MK, Atieno M, Lawn JE, et al. Long-term 
neurodevelopmental outcomes after intrauterine and neonatal insults: 
a systematic review. Lancet 2012;379:445–52.
 7. Lawn J, Davidge R, Paul V, et al. Chapter 5: Preterm baby survival 
and care around the world. In: Howson CP, Kinney MV, Lawn JE, eds. 
Born too soon: the global action report on preterm birth. New York: 
March of Dimes, PMNCH Save the Children, WHO, 2012:60–77.
 8. Turner C, Carrara V, Aye Mya Thein N, et al. Neonatal intensive care 
in a karen refugee camp: a 4 year descriptive study. PLoS One 
2013;8:e72721.
 9. Steer P. The epidemiology of preterm labour. BJOG 2005;112:1–3.
 10. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes 
of preterm birth. Lancet 2008;371:75–84.
 11. Bhattacharya S, Raja EA, Mirazo ER, et al. Inherited 
predisposition to spontaneous preterm delivery. Obstet Gynecol 
2010;115:1125–33.
 12. Jefferson KK. The bacterial etiology of preterm birth. Adv Appl 
Microbiol 2012;80:1–22.
 13. Jones HE, Harris KA, Azizia M, et al. Differing prevalence and 
diversity of bacterial species in fetal membranes from very preterm 
and term labor. PLoS One 2009;4:e8205.
 14. Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm 
prediction study: effect of gestational age and cause of preterm birth 
on subsequent obstetric outcome. National institute of child health 
and human development maternal-fetal medicine units network. Am 
J Obstet Gynecol 1999;181:1216–21.
 15. Romero R, Espinoza J, Kusanovic JP, et al. The preterm parturition 
syndrome. BJOG 2006;113:17–42.
 16. Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of 
malaria in pregnancy. Lancet Infect Dis 2007;7:93–104.
 17. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J 
Pregnancy 2012;2012:1–7.
 18. McGready R, Prakash JA, Benjamin SJ, et al. Pregnancy outcome 
in relation to treatment of murine typhus and scrub typhus infection: 
a fever cohort and a case series analysis. PLoS Negl Trop Dis 
2014;8:e3327.
 19. Osman I, Young A, Ledingham MA, et al. Leukocyte density and 
pro-inflammatory cytokine expression in human fetal membranes, 
decidua, cervix and myometrium before and during labour at term. 
Mol Hum Reprod 2003;9:41–5.
 20. Thomson AJ, Telfer JF, Young A, et al. Leukocytes infiltrate the 
myometrium during human parturition: further evidence that labour is 
an inflammatory process. Hum Reprod 1999;14:229–36.
 21. Yuan M, Jordan F, McInnes IB, et al. Leukocytes are primed in 
peripheral blood for activation during term and preterm labour. Mol 
Hum Reprod 2009;15:713–24.
 22. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many 
causes. Science 2014;345:760–5.
 23. Cao B, Stout MJ, Lee I, et al. Placental microbiome and its role in 
preterm birth. Neoreviews 2014;15:e537–e545.
 24. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between 
bacterial vaginosis and preterm delivery of a low-birth-weight infant. 
The vaginal infections and prematurity study group. N Engl J Med 
1995;333:1737–42.
 25. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate 
flora as risk factors for adverse pregnancy outcome. Best Pract Res 
Clin Obstet Gynaecol 2007;21:375–90.
 26. DiGiulio DB, Callahan BJ, McMurdie PJ, et al. Temporal and spatial 
variation of the human microbiota during pregnancy. Proc Natl Acad 
Sci U S A 2015;112:11060–5.
 27. Kindinger LM, Bennett PR, Lee YS, et al. The interaction between 
vaginal microbiota, cervical length, and vaginal progesterone 
treatment for preterm birth risk. Microbiome 2017;5:6.
 28. Romero R, Hassan SS, Gajer P, et al. The vaginal microbiota of 
pregnant women who subsequently have spontaneous preterm labor 
and delivery and those with a normal delivery at term. Microbiome 
2014;2:18.
 29. Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the 
gut microbiome and metabolic changes during pregnancy. Cell 
2012;150:470–80.
 30. Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during 
pregnancy, birth, and infancy. Front Microbiol 2016;7:1031.
 31. Fowden AL, Forhead AJ. Endocrine mechanisms of intrauterine 
programming. Reproduction 2004;127:515–26.
 32. Gheorghe CP, Goyal R, Mittal A, et al. Gene expression in the 
placenta: maternal stress and epigenetic responses. Int J Dev Biol 
2010;54:507–23.
 33. Callinan PA, Feinberg AP. The emerging science of epigenomics. 
Hum Mol Genet 2006;15 Spec No 1:R95–R101.
 34. Nomura Y, Lambertini L, Rialdi A, et al. Global methylation in the 
placenta and umbilical cord blood from pregnancies with maternal 
gestational diabetes, preeclampsia, and obesity. Reprod Sci 
2014;21:131–7.
 35. Wadhwa PD, Buss C, Entringer S, et al. Developmental origins of 
health and disease: brief history of the approach and current focus 
on epigenetic mechanisms. Semin Reprod Med 2009;27:358–68.
 36. Nilsson R, Björkegren J, Tegnér J. On reliable discovery of molecular 
signatures. BMC Bioinformatics 2009;10:38.
 37. Chaussabel D, Pulendran B. A vision and a prescription for big data-
enabled medicine. Nat Immunol 2015;16:435–9.
 o
n
 28 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023417 on 15 January 2019. Downloaded from 
11Brummaier T, et al. BMJ Open 2018;9:e023417. doi:10.1136/bmjopen-2018-023417
Open access
 38. Heng YJ, Pennell CE, Chua HN, et al. Whole blood gene expression 
profile associated with spontaneous preterm birth in women with 
threatened preterm labor. PLoS One 2014;9:e96901.
 39. Heng YJ, Pennell CE, McDonald SW, et al. Maternal whole blood 
gene expression at 18 and 28 weeks of gestation associated with 
spontaneous preterm birth in asymptomatic Women. PLoS One 
2016;11:e0155191.
 40. Rijken MJ, Mulder EJ, Papageorghiou AT, et al. Quality of ultrasound 
biometry obtained by local health workers in a refugee camp on the 
thai-burmese border. Ultrasound Obstet Gynecol 2012;40:151–7.
 41. Mejias A, Dimo B, Suarez NM, et al. Whole blood gene expression 
profiles to assess pathogenesis and disease severity in infants with 
respiratory syncytial virus infection. PLoS Med 2013;10:e1001549.
 42. Ardura MI, Banchereau R, Mejias A, et al. Enhanced monocyte 
response and decreased central memory T cells in children with 
invasive Staphylococcus aureus infections. PLoS One 2009;4:e5446.
 43. Rinchai D, Anguiano E, Nguyen P. Finger stick blood collection for 
gene expression profiling and storage of tempus blood RNA tubes 
[version 1; referees: 3 approved with reservations]. F1000Research 
2016;5:1385.
 44. Syed Ahamed Kabeer B, Tomei S, Mattei V. A protocol for extraction 
of total RNA from finger stick whole blood samples preserved 
with TempusTM solution [version 1; referees: 1 approved with 
reservations]. F1000Research 2018;7:1739.
 45. Robison EH, Mondala TS, Williams AR, et al. Whole genome 
transcript profiling from fingerstick blood samples: a comparison and 
feasibility study. BMC Genomics 2009;10:617.
 46. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial 
vaginosis is improved by a standardized method of gram stain 
interpretation. J Clin Microbiol 1991;29:297–301.
 47. Livak KJ, Schmittgen TD. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods 2001;25:402–8.
 48. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization 
of real-time quantitative RT-PCR data by geometric averaging of 
multiple internal control genes. Genome Biol 2002;3:research0034.1.
 49. Zheng W, Tsompana M, Ruscitto A, et al. An accurate and efficient 
experimental approach for characterization of the complex oral 
microbiota. Microbiome 2015;3:48.
 50. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows 
analysis of high-throughput community sequencing data. Nat 
Methods 2010;7:335–6.
 51. García-Mena J, Murugesan S, Pérez-Muñoz AA, et al. Airborne 
bacterial diversity from the low atmosphere of greater Mexico City. 
Microb Ecol 2016;72:70–84.
 52. Murugesan S, Ulloa-Martínez M, Martínez-Rojano H, et al. Study of 
the diversity and short-chain fatty acids production by the bacterial 
community in overweight and obese Mexican children. Eur J Clin 
Microbiol Infect Dis 2015;34:1337–46.
 53. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-
checked 16S rRNA gene database and workbench compatible with 
ARB. Appl Environ Microbiol 2006;72:5069–72.
 54. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible 
interactive analysis and graphics of microbiome census data. PLoS 
One 2013;8:e61217.
 55. Lozupone CA, Hamady M, Kelley ST, et al. Quantitative and 
qualitative beta diversity measures lead to different insights into 
factors that structure microbial communities. Appl Environ Microbiol 
2007;73:1576–85.
 56. Chaussabel D, Quinn C, Shen J, et al. A modular analysis framework 
for blood genomics studies: application to systemic lupus 
erythematosus. Immunity 2008;29:150–64.
 57. Bates D, Mächler M, Bolker B, et al. Fitting linear mixed-effects 
models using lme4. 2015;67:48.
 58. Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal 
microbiome in inflammatory bowel disease and treatment. Genome 
Biol 2012;13:R79.
 59. Cheah PY, Lwin KM, Phaiphun L, et al. Community engagement on 
the thai-burmese border: rationale, experience and lessons learnt. Int 
Health 2010;2:123–9.
 60. Thielemans L, Trip-Hoving M, Bancone G, et al. Neonatal 
hyperbilirubinemia in a marginalized population on the thai-myanmar 
border: a study protocol. BMC Pediatr 2017;17:32.
 61. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: 
defining standard protocol items for clinical trials. Ann Intern Med 
2013;158:200–7.
 62. Gilder ME, Zin TW, Wai NS, et al. Gestational diabetes mellitus 
prevalence in Maela refugee camp on the Thai-Myanmar border: a 
clinical report. Glob Health Action 2014;7:23887.
 63. Hunt KJ, Schuller KL. The increasing prevalence of diabetes in 
pregnancy. Obstet Gynecol Clin North Am 2007;34:173–99.
 64. Metzger BE, Lowe LP, Dyer AR, et al. Hyperglycemia and adverse 
pregnancy outcomes. N Engl J Med 2008;358:1991–2002.
 65. Chaussabel D. Assessment of immune status using blood 
transcriptomics and potential implications for global health. Semin 
Immunol 2015;27:58–66.
 66. MacIntyre DA, Chandiramani M, Lee YS, et al. The vaginal 
microbiome during pregnancy and the postpartum period in a 
European population. Sci Rep 2015;5:8988.
 67. Romero R, Hassan SS, Gajer P, et al. The composition and stability 
of the vaginal microbiota of normal pregnant women is different from 
that of non-pregnant women. Microbiome 2014;2:4.
 68. Vinturache AE, Gyamfi-Bannerman C, Hwang J, et al. Maternal 
microbiome - A pathway to preterm birth. Semin Fetal Neonatal Med 
2016;21:94–9.
 69. Shiozaki A, Yoneda S, Yoneda N, et al. Intestinal microbiota 
is different in women with preterm birth: results from terminal 
restriction fragment length polymorphism analysis. PLoS One 
2014;9:e111374.
 70. McGready R, Boel M, Rijken MJ, et al. Effect of early detection and 
treatment on malaria related maternal mortality on the north-western 
border of Thailand 1986-2010. PLoS One 2012;7:e40244.
 o
n
 28 January 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023417 on 15 January 2019. Downloaded from 
